SRPT CLASS ACTION: Sarepta Therapeutics Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by August 25 Legal Deadline (NASDAQ:SRPT)

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Allegations and Claims - The lawsuit alleges that Sarepta misrepresented the safety profile of Elevidys, claiming that the benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance and Market Reaction - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - After a second patient death was reported on June 15, 2025, the stock fell by $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third patient death was disclosed on July 17, 2025, leading to another significant decline in stock price of over 40% on July 18, 2025 [5].